<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03084952</url>
  </required_header>
  <id_info>
    <org_study_id>HB/F2-002/2016</org_study_id>
    <nct_id>NCT03084952</nct_id>
  </id_info>
  <brief_title>Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients</brief_title>
  <official_title>A Phase 2, Randomized, Unicentric Clinical Trial With Dose Scaling for Safety, Tolerability and Efficacy Assessment of 18-Methoxycoronaridine Administered to Cutaneous Leishmaniasis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Infan Industria Quimica Farmaceutica Nacional</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Evandro Chagas National Institute of Infectious Disease</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Infan Industria Quimica Farmaceutica Nacional</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a randomized phase II clinical study, unicentre aimed to evaluate the tolerability,
      safety and efficacy of 18-Methoxyoronaridine as a candidate of tegumentary leishmaniasis
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion Reduction and Re-epithelization - Definitive Cure</measure>
    <time_frame>6 months at the follow-up visit.</time_frame>
    <description>complete epithelization of all ulcers and complete disappearance of inflammatory hardening of all lesions at 6 months at the follow-up visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lesion Reduction and Re-epithelization - Partial Cure</measure>
    <time_frame>6 months at the follow-up visit.</time_frame>
    <description>incomplete epithelialization or incomplete regression of inflammatory hardening of one or more lesions, and without the appearance of new lesions.
Apparent cure: complete epithelization of all ulcers and regression ≥ 70% of the inflammatory hardening of all lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Failure</measure>
    <time_frame>6 months at the follow-up visit.</time_frame>
    <description>Any of the following topics as clinical failure: residual readers with the presence of non-GiemsaDiff-Quick print parasites, or the appearance of new lesions or ≥ 20% increase or no improvement of lesions previously documented.</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Leishmaniasis; American, Cutaneous</condition>
  <condition>Drug Side Effect</condition>
  <arm_group>
    <arm_group_label>1 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>8 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>12 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucantime</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Best dose 18-MC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimum effective dose 18-MC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18-Methoxycoronaridine</intervention_name>
    <description>Drug under evaluation for leishmaniasis treatment</description>
    <arm_group_label>1 mg/day</arm_group_label>
    <arm_group_label>4 mg/day</arm_group_label>
    <arm_group_label>8 mg/day</arm_group_label>
    <arm_group_label>12 mg/day</arm_group_label>
    <arm_group_label>Best dose 18-MC</arm_group_label>
    <arm_group_label>Minimum effective dose 18-MC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucantime</intervention_name>
    <description>Leishmaniasis standard drug in Brazil</description>
    <arm_group_label>Glucantime</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 59 years of age;

          -  Clinical diagnosis of leishmaniasis with at least one ulcerated lesion with evolution
             time from one month;

          -  Parasitological confirmation;

          -  Women of childbearing potential should not be pregnant or breastfeeding, confirmed by
             examination of b-HCG (Gonadotrophic-Chorionic Hormone beta) at the time of screening;

          -  Men and women should use barrier contraceptive methods during the course of the study;

        Exclusion Criteria:

          -  History of any disease or comorbidities that, in the opinion of the investigator, can
             either put the individual at risk or influence the results and ability of the subject
             to participate in the study;

          -  History or presence of gastrointestinal, hepatic, cardiac, renal disease or any other
             known condition that may interfere with the absorption, distribution, metabolism or
             excretion of the investigational product;

          -  Any evidence of underlying serious disease (cardiac, renal, hepatic or pulmonary);

          -  Pregnancy or the patient's unwillingness to use barrier contraceptive methods during
             and 3 months after therapy;

          -  History of gastrointestinal ulcer disease, inflammatory bowel disease, symptoms of
             indigestion;

          -  Any clinically important abnormality in biochemistry, hematology, urinalysis or
             clinical outcomes judged by the investigator;

          -  Any positive screening result for hepatitis B antigens, hepatitis C antibodies, and
             human immunodeficiency virus (HIV);

          -  Any clinically significant abnormalities in the rate, or driving the resting ECG
             morphology that may interfere with the interpretation of the QT interval variations;

          -  History of cancer;

          -  History of drug abuse, judging by the investigator

          -  History of alcohol abuse or excessive alcohol consumption, judged by the investigator;

          -  History of smoking

          -  History of severe allergy / hypersensitivity, judged by the investigator;

          -  History of hypersensitivity to drugs with similar chemical structure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan Carlo Delorenzi, PhD</last_name>
    <phone>+55(11)989780869</phone>
    <email>jancarlo@hebron.com.br</email>
  </overall_contact>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>pharmacokynetics</keyword>
  <keyword>leishmaniasis treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meglumine antimoniate</mesh_term>
    <mesh_term>Ibogaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

